Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
The Journal of Rheumatology|February 1, 2025
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration NetworkMarion Pons, Stylianos Georgiadis, Merete Lund Hetland, et al.
The Journal of Rheumatology|June 15, 2026
Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaborationJette Heberg, Stylianos Georgiadis, Zohra Ahmadzay, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
The Lancet Regional Health. Europe|August 21, 2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Rheumatology (Oxford, England)|June 30, 2026
Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS studyJuan Molina-Collada, Sharon Cowley, Colm Kirby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 17, 2023
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration NetworkPasoon Hellamand, Marleen G H van de Sande, Lykke M Ørnbjerg, et al.
Health Policy (Amsterdam, Netherlands)|April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Annals of the Rheumatic Diseases|July 13, 2026
Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countriesBrigitte Michelsen, Christos Polysopoulos, Michael J Nissen, et al.
RMD Open|May 7, 2026
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritisZohra Faizy Ahmadzay, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, et al.
Pageof 12